Your browser doesn't support javascript.
loading
Amount Change of Peripheral Blood NK Cells in Patients with Hematologic Malignancies and Its Clinical Significance / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 1133-1137, 2015.
Article in Zh | WPRIM | ID: wpr-274080
Responsible library: WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To study the amount change of peripheral blood NK cells in patients with hematologic malignancies and its significance.</p><p><b>METHODS</b>A total of 200 patients with hematologic malignancies in our hospital from June 2013 to March 2015 were chosen as study objects, out of them 105 patients were in aute stage and 95 patients were in remisson stage. At same time 100 people from healthy medical examination in our hospital were chosen as control group. The mumber change and subgroups of their peripheral blood NK cells were analyzed and compared.</p><p><b>RESULTS</b>In control group the absolute number of NK cells was (412.91 ± 167.35)/µl, the relative number of NK cells was (13.31 ± 2.56) %; in group at acute stage of leukemia the absolute number of NK cells was (97.84 ± 23.18)/µl, the relative number of NK cells was (6.79 ± 0.78) %; in group at acute stage of lymphoma, the absolute number of NK cells was (101.79 ± 25.63)/µl, and the relative number of NK cells was (7.12 ± 1.03) %; in group at remission stage of leukemia, the absolute number was (297.17 ± 87.56)/µl, and the relative number was (10.15 ± 1.64) %; In group at remission of lymphoma, the absolute number of NK cells was (288.52 ± 118.52)/µl, and the relative number of NK cells was (10.82 ± 1.97) %. The number of NK cells between different groups showed statistical difference (P < 0.05). In remission group, the number of NK cells before and after treatment had statistical difference (P < 0.05). In control group, the number of CD56(bright) subgroup was (25.28 ± 4.72) %, the number of CD56(bright) subgroup at the acute stage of leukemia was (65.46 ± 11.21) %, and the number of CD56(bright) subgroup at the acute stage of lymphoma was (70.71 ± 12.14) %, the number of CD56(bright) subgroup at remission stage of leukemia was (23.35 ± 4.67) %, the number of CD56(bright) subgroup at remission stage of lymphoma was (24.89 ± 4.58) %. The number of CD56(bright) subgroup between different groups showed statistical significance (P < 0.05).</p><p><b>CONCLUSION</b>The number and function of peripheral blood NK cells in patients with hematologic malignancies have been confirmed to be obvious decrement, but after treatment the number of NK cells in those patients showed increment.</p>
Subject(s)
Full text: 1 Index: WPRIM Main subject: Killer Cells, Natural / CD56 Antigen / Hematologic Neoplasms Limits: Humans Language: Zh Journal: Journal of Experimental Hematology Year: 2015 Type: Article
Full text: 1 Index: WPRIM Main subject: Killer Cells, Natural / CD56 Antigen / Hematologic Neoplasms Limits: Humans Language: Zh Journal: Journal of Experimental Hematology Year: 2015 Type: Article